The Lancet Haematology
Fecha de publicación: 1 december 2018
DOI: https://doi.org/10.1016/S2352-3026(18)30181-9
Autores: Oliver Ottmann
Background: Before the advent of tyrosine kinase inhibitor (TKI) therapy, Philadelphia chromosome-positive acute lymphoblastic leukaemia had an exceptionally poor prognosis and was a clear indication for allogeneic haemopoietic stem cell transplantation (HSCT). Adding TKIs to frontline therapy improves survival, with transplantation in paediatric patients increasingly reserved for those with poor response.
Comentarios
Para dejar un comentario antes debes iniciar sesión:
¿No tienes una cuenta?
Regístrate a través de éste enlace.